Steven D Wiley

US Patent:

20010010925, Aug 2, 2001

Filed:

Nov 17, 1997

Appl. No.:

08/971317

Inventors:

STEVEN R. WILEY - LIBERTYVILLE IL, US

International Classification:

A01N037/18
A61K038/00
C12Q001/68
G01N033/53
G01N033/567
C07H021/04
A61K031/70
A01N043/04
C12P021/06
A61K039/00

US Classification:

435/069100, 536/023500, 536/023510, 530/324000, 514/044000, 424/198100, 424/203100, 424/185100, 435/007100, 530/387900, 530/388240, 435/007200, 514/002000, 435/320100, 435/006000

Abstract:

An isolated clone consisting of sequences transcribed from the TNF-delta gene is disclosed. Also provided are human polypeptides translated from said TNF-delta sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TNF-delta, which may be used to treat deficiencies of TNF-delta and diseases conditions ameliorated by TNF-delta. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TNF-delta associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TNF-delta, especially inflammation. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases associated with TNF-delta, including but not limited to inflammation is also disclosed. Illustrative sequences and clone designations for TNF-delta are provided.

US Patent:

61717878, Jan 9, 2001

Filed:

Jun 26, 1997

Appl. No.:

8/883086

Inventors:

Steven R. Wiley - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

An isolated clone consisting of sequences transcribed from the TNF-gamma gene. Also provided are human polypeptides translated from said TNF-gamma sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TNF-gamma, which may be used to treat deficiencies of TNF-gamma and diseases conditions ameliorated by TNF-gamma. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TNF-gamma associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TNF-gamma, especially inflammation. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases associated with TNf-gamma, including but not limited to inflammation. Illustrative sequences and clone designations for TNF-gamma are provided.

US Patent:

62076426, Mar 27, 2001

Filed:

Jun 26, 1998

Appl. No.:

9/105343

Inventors:

Steven R. Wiley - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K38/18
7
C07K14/46

US Classification:

514 12

Abstract:

An isolated clone consisting of sequences transcribed from the TREPA gene. Also provided are human polypeptides translated from said TREPA sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TREPA, which may be used to treat deficiencies of TREPA and diseases conditions ameliorated by TREPA. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TREPA-associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TREPA, especially inflammation. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases associated with TREPA, including but not limited to inflammation. Illustrative sequences and clone designations for TREPA are provided.

US Patent:

50825739, Jan 21, 1992

Filed:

Jul 24, 1990

Appl. No.:

7/557252

Inventors:

Joel M. Goldstein - Ambler PA
Vina Patel - Lansdale PA
Steven J. Wiley - Willow Grove PA

Assignee:

Aquarium Pharmaceuticals, Inc. - Chalfont PA

International Classification:

C02F 120

US Classification:

210749

Abstract:

A method for detoxifying ammonia in an ammonia-containing aquatic system comprises adding to the system a novel composition comprising an amine-based ammonia detoxifying solution in an amount effective to detoxifying substantially all of the ammonia, where the solution is non-toxic and has a pH suitable for aquatic life. Further, a method for detoxifying contaminants selected from the group consisting of ammonia, chlorine and chloramine from a contaminated aquatic system comprises adding to the system a novel composition contaminant according to the present detoxifying solution in an amount effective to detoxifying the contaminants, the solution comprising an amine-based ammonia detoxifying compound and a dechlorinator, where the solution is stable, non-toxic and has a pH suitable for aquatic life. In addition, methods for preparing the ammonia detoxifying and contaminant detoxifying compositions and the compositions produced thereby are disclosed.

US Patent:

52118720, May 18, 1993

Filed:

May 7, 1991

Appl. No.:

7/696689

Inventors:

Joel M. Goldstein - Ambler PA
Vina Patel - Lansdale PA
Steven J. Wiley - Willow Grove PA

Assignee:

Aquarium Pharmaceuticals, Inc. - Chalfont PA

International Classification:

C02F 512
C02F 510

US Classification:

252180

Abstract:

The present invention is a solution for detoxifying contaminants, such as ammonia, chlorine and chloramine, in aquatic systems. The solution includes a composition of an amine-based ammonia detoxifying compound, in an amount effective to detoxify substantially all of the ammonia, and a dechlorinator. An aqueous solution of the amine-based compound is acidified to adjust the pH to form a stable, non-toxic solution suitable for aquatic life. In addition, methods for preparing the detoxifying solution are disclosed.